SCHEMBL5110019

SCHEMBL5110019

CCC(C(=O)O)c1cccc(Oc2ccccc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.67
MEN1 O00255 1/20 0.56
CYP2D6 P10635 1/20 0.56
KMT2A Q03164 1/20 0.56
AKR1C3 P42330 6/20 0.54
AKR1C2 P52895 5/20 0.54
AKR1C1 Q04828 1/20 0.54
ALOX5 P09917 1/20 0.54
FFAR1 O14842 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MME P08473 1/20 0.46
ACE P12821 1/20 0.46
CPA1 P15085 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
GLI1 P08151 1/20 0.46
GLI2 P10070 1/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28575917 0.88 PTGS1 (0.56) PTGS1MEN1CYP2D6KMT2AAKR1C3
SCHEMBL2020322 0.87 AKR1C3 (0.70) PTGS1AKR1C3AKR1C2AKR1C1
SCHEMBL11537584 0.87 PTGS1 (0.55) PTGS1MEN1CYP2D6KMT2AALOX5
SCHEMBL14280733 0.87 PTGS1 (0.51) PTGS1MEN1CYP2D6KMT2AAKR1C3
SCHEMBL6649963 0.86 PTGS1 (0.51) PTGS1MEN1CYP2D6KMT2AAKR1C3
Water SCHEMBL11762224 0.86 PTGS1 (0.54) PTGS1MEN1CYP2D6KMT2AAKR1C3
Water SCHEMBL11762220 0.86 PTGS1 (0.54) PTGS1MEN1CYP2D6KMT2AAKR1C3
SCHEMBL30371750 0.85 PTGS1 (0.64) PTGS1MEN1CYP2D6KMT2AAKR1C3
SCHEMBL7380424 0.84 PTGS1 (0.68) PTGS1MEN1CYP2D6KMT2AAKR1C3
SCHEMBL11157909 0.84 AKR1C3 (0.53) PTGS1AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332516-B2 Geminally di-substituted NSAID derivatives as Aβ42 lowering agents MERCK + CO., INC. (US) 2008-02-19 US disclosed
EP-1587798-A4 GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS MERCK & CO INC (US) 2007-06-27 EP disclosed
US-20060063937-A1 Geminallyl di-substituted nsaid derivatives as abeta 42 lowering agents MERCK SHARP & DOHME CORP. 2006-03-23 US disclosed
EP-1587798-A2 GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS Merck & Co., Inc. (US) 2005-10-26 EP disclosed
WO-2004064771-A2 GEMINALLY DI-SUBSTITUTED NSAID DERIVATIVES AS ABETA 42 LOWERING AGENTS MERCK & CO., INC. (US) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063937-A1 Geminallyl di-substituted nsaid derivatives as abeta 42 lowering agents APP, PSEN1, CA1 PTGS1 20/4885MEN1 1296/4885CYP2D6 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.